Back to Trades
Total Value
$253.2K
Filing Date
Jun 25, 2026
1 transactions
Trade Summary
On Jun 24, 2026, Gaslightwala Abizer, CEO, Director, reported $253.2K of Akari Therapeutics Plc (AKTX) across 1 transactions. The filing covers company securities and reflects balanced net activity of $0. Reported prices ranged from $4.64 to $14.63. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Akari Therapeutics Plc
- Ticker Symbol
- AKTX
- CIK
- 0001541157
Insider Information
- Role
- CEO, Director
- Location
- TAMPA, FL
Filing Details
- Filing Date
- Jun 25, 2026
- Transaction Date
- Jun 24, 2026
- Accession Number
- 0001493152-26-030207
- Form Type
- 4
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jun 24, 2026 | AKTX derivative | 5,500 | $4.64 | Grant/Award | $25.5K |
| Jun 24, 2026 | AKTX derivative | 15,563 | $14.63 | Grant/Award | $227.7K |
Want live alerts when Gaslightwala Abizer trades again?
Download Insider Trades to track AKTX, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)On April 1, 2026, the reporting person was granted an option to purchase 15,000 American Depositary Shares, with each American Depositary Share representing 80,000 ordinary shares with a par value of $0.000000005 per ordinary share. The option vests in three installments based on the closing of qualified financings of at least $15,000,000 in gross proceeds on or before June 30, 2026. The Issuer closed a qualified financing of $5,500,000, resulting in the vesting of the option as to 5,500 American Depositary Shares.